3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
24
Neoplasms
12
Colonic Neoplasms
12
Breast Neoplasms
12
Prostatic Neoplasms
9
Polycythemia Vera
9
Venous Thromboembolism
8
Multiple Myeloma
8
Recurrence
5
Rectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Thrombocythemia, Essential
4
Ovarian Neoplasms
4
Neoplasms, Plasma Cell
4
Neoplasm Metastasis
4
Myeloproliferative Disorders
4
Barrett Esophagus
4
Precancerous Conditions
3
Melanoma
3
Esophageal Neoplasms
3
Adenomatous Polyps
3
Adenoma
3
Tobacco Use Disorder
2
Thrombosis
2
Thromboembolism
2
Smoking Cessation
2
Sarcoma
2
Primary Myelofibrosis
2
Neoplastic Cells, Circulating
2
Neoplasms by Site
2
Interventions
pembrolizumab
3
Pemetrexed
2
Cholecalciferol
2
relacorilant
1
glutathione pegylated liposomal doxorubicin
1
ficlatuzumab
1
bosutinib
1
Trastuzumab
1
Sunitinib
1
Morphine
1
Methadone
1
MRX-2843
1
Letrozole
1
Imatinib Mesylate
1
Electrochemotherapy
1
Control Groups
1
Clomiphene
1
Cisplatin
1
Carboplatin
1
Bleomycin
1
Bevacizumab
1
Azacitidine
1
Aspirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pathologic Processes
×
Aspirin
×
Clear all
NCT03464305
2024-03-19
ASPIRIN
University Hospital, Antwerp
Phase 3
Active not recruiting
148 enrolled